Press Releases

Press Releases

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Lwolffe@wheelhouselsa.com

Date Title and Summary Additional Format
April 13, 2021 Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after successful $150 million follow-on offering in March 2021 SAN FRANCISCO, April 13, 2021 (GLOBE NEWSWIRE)
April 7, 2021 Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th
March 16, 2021 Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
March 10, 2021 Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
March 9, 2021 Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of
March 9, 2021 Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at the following
March 4, 2021 Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of
March 2, 2021 Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.
February 16, 2021 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million
January 7, 2021 Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
Expansion of agreement results in an additional payment of $22 million to Nurix SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic
Displaying 1 - 10 of 11